SUBSCRIBE: Digital / Print / eNewsletter
Expert: Expectations are high that biosimilars can control overall biologic cost growth.
PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the ...
The presidential hopefuls have very different views about the ACA. Expect three healthcare things that will stay the same ...
Executives need to ask themselves four key questions to mitigate the negative impact of rising drug costs.
As ACOs continue to grow in the healthcare sector, it is imperative that a liaison is in place to act as an intermediary ...
Here’s what to expect from Blue Shield of California’s four-day closure over Obamacare losses.
A retrospective case study in Brazil examines whether the Zika virus has ties to a birth defect other than microcephaly. ...
What has you counting sheep at night? Answers from your peers may surprise you.
We want to know what you think about the top challenges facing the industry. Please take our quick survey. You’ll be entered to win a $200 Visa gift card.
Advanced job search